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of activists laid siege to the FDA offices in 
Washington DC. They fought against the 
mechanisms that were being used to approve 
new medicines against HIV. This rise of ac-
tivism was fuelled by anger at the seeming 
lack of progress in releasing the new anti-
virals to patients in need, and fuelled by the 
lack of a patient voice in the decision-making 
processes [2].
Although this action in 1988 should have 
sounded an alarm for including the patients 
in decisions, scientists, clinicians and deci-
sion makers were already pursuing another 
course. The principle of Evidence Based 
Medicine (EBM) had become the vehicle 
by which patients would truly benefit. Only 
evidence with the highest epistemological 
strength (i.e., coming from meta-analyses, 
systematic reviews, and randomized con-
trolled trials) should yield strong recom-
mendations in guidelines [3]. Also regula-
tory authorities strengthened their evidence 
requirements from the viewpoint of EBM for 
market authorization. Hence, pharmaceutical 
companies adapted their development pro-
cess to yield the quality data appropriate for 
supporting product authorization and adop-
tion to standard practice. However, this push 
for better evidence still left out the patient. 
It was the scientists and experts who deter-
mined which evidence to use, often resulting 
in measures that meant little to the daily life 
of a person with a disease.
The principles of EBM were adopted by 
a new group of stakeholders in the 1990s, 
Health Technology Assessment bodies. EBM 
provided the foundation for assessing the val-
ue of new pharmaceuticals, but, in contrast 
to the traditional clinical endpoints which of-
ten were surrogate markers for an expected 
health impact, HTA bodies began asking for 
evidence that demonstrated actual outcomes 
relevant to patients.
Because HTA decision-makers had to rec-
ommend priorities in listing or reimburse-
Working in the world of healthcare, the last 
few years have seemed like the beginning 
of a revolution, and this revolution has a 
rallying cry: Patient Centricity. Suddenly, 
it seems that all the actors in the healthcare 
system have woken up to the fact that pa-
tients deserve to be central to the healthcare 
and technological decisions that affect them. 
Wouldn’t you think that patients have been 
in the centre of medicines since Hypocrates 
of Cos stated almost 2500 years ago that 
their diseases have natural causes and that 
the course of the disease can be influenced 
by medicines? However, for many hundred 
years, the science of developing medicines 
has been driven by an authoritative approach 
to experimentation with patients as subjects 
rather than genuine participants in these tech-
nological developments.
Even quite recently, many medicines were 
developed purely through the championship 
of one expert, with the science at the centre of 
the innovation and with limited consideration 
of the needs and wants of the patients, and 
thus, the overall outcome. Only after disas-
trous adverse events caused by some thera-
pies marketed in the nineteen-fifties such as 
thalomide or animal cell therapy, regulatory 
requirements were introduced which made 
safety data, risk evaluation and pharmacovig-
ilance processes an important part of medi-
cines development [1]. In addition, prescrip-
tion laws were introduced or intensified to 
protect patients from uncontrolled overuse. It 
became important for the healthcare system 
and pharmaceutical companies to better un-
derstand prescribers’ behaviours and needs. 
To prevent failures in the market, interactions 
with prescribers began to happen throughout 
the clinical development – but where was the 
patient in this?
Perhaps we can trace the moment when pa-
tients first started to fight against a system 
which locked them out of the decision pro-
cess to October 11, 1988 when a large group 
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ment, they expected to see scientifically ro-
bust outcomes data for the new product in 
comparison to the current standard of care. 
Furthermore, HTA processes embraced also 
the questions for economic, ethical and legal 
consequences [4].
Being faced with product evaluations from 
the perspective of a payer or a healthcare 
system, the pharmaceutical industry swiftly 
established processes which allowed early 
challenge of the development plans from this 
viewpoint and appropriate improvements to 
better meet HTA needs [5].
If the HIV community’s battle with the FDA 
was a plea for a more patient-centred regula-
tory system, then the focus on patient relevant 
outcomes at the HTA level raised the debate 
to one about patient values. In retrospect, we 
see this as the next big step for patients in 
moving to the centre.
As HTA bodies were grappling with the con-
cept of patient relevance and what this meant 
for the evidence that they would require, 
patients themselves were becoming much 
more connected, informed and assertive. 
Today, patients and caregivers network, col-
laborate, and have become organized. They 
have learnt how decisions are made. Patient 
organizations have fought against decisions 
which were made without them but which, 
in their view, have an impact on their health. 
Therefore, regulatory and HTA agencies have 
started to include patients or citizens perspec-
tives into their decisions and in some cases as 
partners in their assessment of new technolo-
gies [6].
A few stumbling blocks have appeared along 
the way towards participatory decision mak-
ing or Patient and Public Involvement (PPI), 
one of the most important being the com-
munication between the different stakehold-
ers (clinical, researchers, patients, citizens). 
Industry players have struggled to determine 
the best way to engage patients and many 
barriers exist, but there is a new determina-
tion to overcome them [7]. A range of train-
ings for patients or citizens have been devel-
oped to give them the base understanding of 
good research and clinical practices as well 
as decision making in healthcare. Online 
trainings and guidance (e.g., EULAR [8]) or 
certification courses (e.g. EUPATI [9]) are 
available for those patients who want to be-
come more engaged in research and health-
care decisions. Now it finally is time for the 
pharmaceutical research and development 
community to conduct their research with the 
patients as partners in this scientific journey. 
The concept of patient centricity needs to be-
come action, not just words. To become truly 
patient centric the patient perspective needs 
to percolate the innovation chain throughout 
research and development.
What can go wrong without involving pa-
tients actively? There are many examples 
of therapeutics which were developed with 
good intentions but wrong assumptions 
about patient needs, behaviours or tolerance 
for clinical trial settings. A fairly recent one 
is the discontinuation of the inhaled insu-
lin product Exubera, marketed by Pfizer. 
Many elements combined to make the up-
take of this new form of insulin so slow; 
the inhaler device was large, and there were 
patient concerns about the predictability of 
the dose of insulin that would be provided. 
Despite successful clinical programs that 
convinced regulators of its efficacy and 
safety, payers and some patients were less 
convinced [10].
So, the insights from patients can be criti-
cal for the successful adoption of innova-
tions. How do current patient advocates see 
the need for being involved in research and 
development? In 2014, we asked a group 
of 40 patient advocates representing differ-
ent disease areas and different geographies 
about their expectations and viewpoints 
concerning patient involvement in the de-
velopment of medical innovation [11]. The 
majority wanted to see a higher involvement 
of patients in the entire process of clinical 
research and in any research with impact 
on clinical decision making, listing or re-
imbursement decisions. Many of them had 
experiences originating from formal (e.g. 
HTA process), informal (e.g. lobbying), or 
destructive levels (e.g., litigation) of en-
gagement. The participants identified a long 
list of expected improvements through PPI, 
which can be summarized into six clusters as 
shown in in Figure 1.
One of the conclusions of our survey in 2014 
was that best practices need to be developed 
urgently across the development pathway to 
ensure high quality patient participation. This 
is still a valid conclusion in 2016. Meanwhile, 
many organisations are striving to develop 
such standards by collaborating across stake-
holder groups, by creating pilot programs for 
clinical research development, by involving 
patients and citizens in the decision-making 
on adoption and reimbursement for new 
Figure 1. Summary of expectations from patients being actively involved in clinical research as reported in a survey of 40 patient 
advocates in 2014 [11]
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technologies, and by evaluating the impact 
of such involvement across all activities. 
Several studies have started to evaluate the 
impact of PPI in early research, in medicines 
development or in reimbursement decisions 
[12-14]. It should be added that evaluation of 
impact and experiences in combination with 
improvement mechanisms are core elements 
of developing effective PPI processes over 
the next years.
Critiques may say that not every patient is in 
the position or willing to become part of the 
innovation or decision process [15]. While 
this is probably true, there is no reason to 
exclude those who are willing to participate 
and contribute. They can provide valuable in-
sights in order to make healthcare and medi-
cal research more relevant to patients. In fact, 
there are many examples, where patients or 
their caregivers themselves are prioritizing, 
financing, or organizing innovation such as 
the Téléthon movement in France which is 
supporting impressive research activities 
purely driven by PPI [16]. In addition, there 
are many examples of patient organisations 
actively surveying patients for their experi-
ences with their therapies in ways and words, 
which are relevant to them (patient based ev-
idence) [17,18]. Thus, patients have already 
learned to speak the fully differentiated lan-
guage of innovation and will not be treated 
only as subjects of research. The rest of us 
should listen, learn and take action.
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